Integrating new targeted agents into the treatment of non-small-cell lung cancer.
Authors
Thatcher, NickAffiliation
Christie and Wythenshawe Hospitals, Manchester, UK. nick.thatcher@christie-tr.nwest.nhs.ukIssue Date
2006-12
Metadata
Show full item recordAbstract
Lung cancer is the most common cause of cancer-related deaths worldwide, and the discovery and implementation of more effective therapy remains challenging. The development of agents that target the epidermal growth factor receptor/human epidermal growth factor receptor 1 (EGFR/HER1) signal transduction pathway have provided a class of novel targeted therapies that are applicable in the treatment of non-small-call lung cancer (NSCLC). Current challenges include the determination of how best these promising new agents can be integrated into current methods of treatment for patients with NSCLC, and clarification of the extent to which early lines of treatment can influence outcome in the later stages.Citation
Integrating new targeted agents into the treatment of non-small-cell lung cancer. 2006, 54 Suppl 2:S25-31 Lung CancerJournal
Lung CancerDOI
10.1016/j.lungcan.2006.09.012PubMed ID
17056150Type
ArticleLanguage
enISSN
0169-5002ae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2006.09.012
Scopus Count
Collections
Related articles
- Targeted therapies for non-small cell lung cancer.
- Authors: Dempke WC, Suto T, Reck M
- Issue date: 2010 Mar
- New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
- Authors: Crawford J
- Issue date: 2003 Jan
- Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
- Authors: Burris HA 3rd
- Issue date: 2009 Aug
- Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
- Authors: Patel JD
- Issue date: 2006 Nov
- Epidermal growth factor receptor as a target in cancer therapy.
- Authors: Kim ES
- Issue date: 2003 Jan